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1. Introduction 
Warfarin, one of the most commonly used oral anticoagulant in the US and across the globe, 
is a drug of choice for millions. It’s a unique drug of its kind due to the multiple 
pharmacological and pharmacokinetic properties. The posology of warfarin cannot be 
generalized. Having the right dose for the right patient makes this drug follow a pattern that 
is unique among the lot. Warfarin has a high interpatient variability (Min-Jung Kwon et al., 
2009) and narrow therapeutic index which requires continuous monitoring of its plasma 
concentration, the prothrombin time and the international normalized ratio followed by a 
dosage adjustment. Warfarin in pure form exists as a racemic mixture consisting of equal 
amounts of R and S enantiomers (Porter et al., 1986). The S enantiomer is more potent than 
the R form (Breckenridge et al., 1974). Warfarin is highly metabolized in the body in a stereo 
specific pathway catalyzed by cytochrome P450. R-warfarin is metabolized primarily by 
CYP1A2 to 6- and 8-hydroxy warfarin, and by CYP3A4 to 10-hydroxy warfarin, while S- 
warfarin is metabolized primarily by CYP2C9 to 7-hydroxy warfarin (Kaminsky and 
Zhang., 1997). The properties of warfarin, such as narrow therapeutic index, high protein 
binding, CYP dependent metabolism and a very high elimination half life render to be prone 
to many drug interactions (Chan et al., 2009). Elimination half life of warfarin is relatively 
long (10-16 hours in animals and 40-46 hours in humans), causing a dramatic increase in the 
anticoagulant effect upon concomitant administration of warfarin with other drugs causing 
drug-drug interactions (Alexander and Areg et al., 2009).  
Etravirine is the first drug in the second generation of non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) for HIV/AIDS. The drug was recently marketed for the treatment of 
HIV infection. It is of great advantage in combination with other antiretrovirals in the 
treatment of patients who are on this regimen for a considerable period of time. (Martha 
Boffito et al., 2009). Etravirine is highly bound to plasma proteins and is primarily 
metabolized by CYP450; 3A4, 2C9 and 2C19 iso-enzymes. Potential drug interactions of 
warfarin and etravirine are expected due to their high protein binding and similar hepatic 
metabolic characteristics. For most antiretrovirals it’s critical that drug concentrations are 
maintained above the suggested minimum effective concentration throughout the dosing 
interval. Suboptimal antiretroviral exposure may permit viral replication and predispose to 
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the selection of drug-resistant virus. Resistant strains may hence lead to disease progression 
and treatment failure (Martha Boffito et al., 2009). On the other hand, long term use of 
NNRTIs can potentially cause HIV related thromboembolic events, which requires the use 
of the anticoagulant warfarin. A clinically significant etravirine-warfarin interaction could 
occur after their concomitant administration (Welzen et al., 2011).  
Several LC-MS/MS methods have been developed for the analysis of etravirine in human 
plasma samples. For example, (Heine et al., 2009) developed an LC-MS/MS method 
quantifying etravirine in human plasma, dry blood spot, and peripheral blood 
mononuclear cell lysate. LC-tandem MS methods were also available for simultaneous 
analysis of etravirine with other NNRTIs (Fayet et al., 2009; Else et al., 2010) in human 
plasma and with protease inhibitors (Quaranta et al., 2009). All the above referenced 
methods used a direct plasma protein precipitation using organic co-solvent and had 
etravirine detection limit of > 10 ng/mL, except for a study by (Rezk et al., 2009), where a 
2 ng/mL detection limit was reported. Most of these LC-MS/MS methods were aimed for 
and been used for clinical drug monitoring. Few have been used for pharmacokinetic 
characterization of potential drug-drug interactions between etravirine and other 
concomitantly administered drugs. For example, Scholler-Gyure et al., 2008 validated and 
applied an LC/MS/MS method of etravirine for a pharmacokinetic drug-drug interaction 
study between etravirine and acid-suppressing agents in healthy human volunteers. 
However, very limited analytical methods are currently available for the determination of 
etravirine in rat plasma. Furthermore, there are no analytical methods till date for the 
simultaneous determination of racemic warfarin and etravirine in the rat plasma. 
Developing such analytical method is necessary for further characterization and 
evaluation of factors that affect the absorption and disposition of etravirine and warfarin. 
Hence it is a highly significant to develop an analytical method for the simultaneous 
determination and validation of racemic warfarin and etravirine to extrapolate its 
applicability in pharmacokinetic studies of these compounds. In the current study, we 
were successful in coming up with an LC-MS/MS determination of racemic warfarin and 
etravirine in rat plasma which can be of high relevance in the pharmacokinetic profiling of 
both etravirine and warfarin. The limit of detection was as low as 1ng/mL and the 
injection volume used was 10ul without any interference with the sensitivity of the assay. 
The total run time of 11 minutes permitted the assay to be carried out in a relatively short 
time period with minimal consumption of the solvents and reagents.  
Therefore, the objective of this study is to develop a simultaneous LC-MS/MS method 
suitable for determination and quantification of R-warfarin, S-warfarin, and etravirine in rat 
plasma. The method has been validated and applied to a pharmacokinetic evaluation of the 
drug-drug interaction between warfarin and etravirine using rat as an animal model. 
2. Materials and methods  
2.1 Chemicals 
Racemic warfarin standard powder was purchased from Sigma Aldrich Co. (Missiouri, St. 
Louis, USA). Etravirine as the standard powder was purchased from Toronto research 
chemicals Inc. (Canada). Acetaminophen and acetic acid was purchased from Sigma Aldrich 
Co. (Missiouri, St. Louis, USA). HPLC graded water was purchased from Mallinckrodt 
Baker, Inc. (New Jersey, Phillipsburg, USA). Acetonitrile HPLC grade was purchased from 
VWR international Chemicals (Pennsylvania, West Chester, USA).The chemical structures 
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and fragmentation patterns for racemic warfarin, etravirine, and the internal standard 
acetaminophen are presented in Figure 1. 
 
 
 
 
 
 
Fig. 1. Part I. 
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Fig. 1. Part II. 
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Part III. 
Fig. 1. Chemical structures and fragmentation patterns for racemic warfarin (A), etravirine 
(B) and internal standard, acetaminophen (C). 
2.2 LC/MS/MS conditions 
Warfarin, etravirine and the IS were analyzed by using an Agilent 1200 series HPLC system 
(Foster city, CA) using a commercially available chiral column, Lux cellulose -1 with a 
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dimension of 250X4.6mm i.d. packed with 5µm particles (Phenomenex, Torrance, CA, USA) 
in conjunction with a Lux Cellulose-1 guard column with a dimension of 4 x 3.0mm 
(Phenomenex, Torrance, CA, USA). A gradient elution was used, consisting of 0 .1% acetic 
acid in water (mobile phase A) and 100% acetonitrile (mobile phase B). The gradient started 
with mobile phase A and B being mixed at a ratio of 40:60 %v/v respectively, at a flow rate 
of 1.5mL/min till 4.5 minutes. At time 4.5-6 minutes, A and B were mixed at a ratio of 40:60 
% v/v respectively, at a flow rate of 1.3 mL/min. From 6-9.1 minutes, the mobile phase was 
solely comprised of B, at a flow rate of 1.5mL/min. At 9.1-11 minutes, A and B were mixed 
at a ratio of 40:60 %v/v, at a flow rate of 1.5 mL/min. Two minutes was allowed at the end 
of each run for equilibration. The injection volume was 10ul and the total run time was 11 
minutes. The column effluent was monitored using a 3200 QTRAP ® LC-MS/MS (AB Sciex, 
Foster city, CA) which is a hybrid triple quadrupole linear ion trap equipped with a 
TurboIonspray ion source. A Parker Balston Source 5000Tri Gas generator was used to 
generate pure nitrogen. The nebulizer gas and the heater gas were maintained at 80psi and 
the ion spray heater was set at 6500C. Ion spray needle voltage was 4500 V, the curtain gas 
was 30psi and the collision gas was set to medium. The mass spectrophotometer was set at 
the negative mode. The transition ions were detected using multiple reaction monitoring 
from a specific parent ion to product ion for etravirine (m/z 433.3142.1), racemic warfarin 
307.4161.3 and acetaminophen 150107.1. Peak areas and other compound parameters 
were determined by Analyst R software, ver.1.5. 
2.3 Preparation of standards and calibration curves  
Individual stock solutions of racemic warfarin, acetaminophen and etravirine (1mg/mL) 
were prepared by dissolving 25mg of each substance in 25mL of respective solvents 
(acetonitrile for racemic warfarin and acetaminophen, DMSO for etravirine) and stored in 
refrigerator at 4°C. All the working solutions were freshly prepared daily. For quantitative 
analysis, a series of working standard mixtures were prepared by mixing and diluting the 
stock solutions of racemic warfarin and etravirine with mobile phase to yield concentrations 
of 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5 µg/mL. A working solution of IS was prepared by 
diluting the stock solution of acetaminophen with acetonitrile to yield a final concentration 
of 500ng/mL. In vivo standard curves were prepared by spiking blank plasma with 
warfarin and etravirine standard solutions to yield calibration standards in plasma at 
concentrations of 2.5, 5, 10, 25, 50, 100, 250 and 500 ng/mL.  
2.4 In vivo sample preparation 
The rat plasma was collected from male Sprague Dawley rats in our laboratory and stored at 
-800C until its use. Each warfarin and etravirine containing rat plasma sample (100µl) was 
extracted and deproteinized by mixing it with 100µl of IS working solution containing 500ng 
of acetaminophen per mL of acetonitrile. The mixture was briefly vortexed for 1 minute and 
centrifuged at 13,000 rpm for 10 minutes. A 10 µl of the supernatant was directly injected in 
to the HPLC column. Calibration curves were plotted by peak area ratio of each analyte and 
internal standard vs. concentrations in rat plasma.  
2.5 Assay validation 
The “Guidance for Industry – Bioanalytical Method Validation” document from FDA was 
used as a guide for the assay validation described as follows (FDA. 2001). 
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2.5.1 Linearity, accuracy, precision, and recovery 
Linear calibration curves in rat plasma were generated by plotting peak area ratios of 
racemic warfarin and etravirine to the IS versus seven known plasma racemic warfarin and 
etravirine concentrations over the range of  2.5-500 ng/mL. Slope, intercept, and coefficient 
of determination values were estimated using least square regression analysis. Quality 
control plasma samples containing low (10ng/mL), medium (100ng/mL), and high 
(400ng/mL) racemic warfarin and etravirine concentrations were used to evaluate the 
precision and accuracy of the assay method. The intra-day assay precision and accuracy 
were obtained by analyzing six replicates of the quality control samples using calibration 
curves constructed on the same day. The inter-day assay precision and accuracy were 
obtained by analyzing six quality control samples using calibration curves constructed on 3 
different days. The assay precision was reflected by the relative standard deviation and the 
assay accuracy was reflected by the relative percentage error from the theoretical drug 
concentrations. The limit of detection (LOD) was defined as the plasma concentration that 
yielded a peak height equal to three times that of baseline noise. The lowest limit of 
quantification (LLOQ) was selected as the lowest racemic warfarin and etravirine plasma 
level on the calibration curve. The extraction recoveries of racemic warfarin and etravirine 
from rat plasma (expressed as a percentage) were calculated as the ratio of the slope of a 
calibration curve for racemic warfarin and etravirine in spiked plasma to that of spiked 
mobile phase. 
2.5.2 Stability 
Three aliquots of the low, medium, high concentration QC samples were used to conduct 
each of the following sets of stability tests: three freeze-thaw cycles, storage under 
refrigeration conditions (4oC), and storage at room temperature in autosampler.  
2.5.3 Matrix effects 
Matrix effects from endogenous substances present in extracted rat plasma may cause ion 
suppression or enhancement of the signal. Matrix effects were assessed by comparing the 
peak areas of racemic warfarin and etravirine after addition of low, medium, and high (n=3 
each) concentrations of racemic warfarin and etravirine to (A) mobile phase and (B) and 
supernatant of extracted blank plasma. The peak area ratio of B/A (as a percentage) or the 
percentage matrix factor was used as a quantitative measure of matrix effect. The absolute 
matrix effect was quantified by using the “post extraction spike method” which compares 
the average peak area ratios of a group of standard samples diluted in mobile phase (group 
A) and another group spiked into plasma after plasma extraction (group B). Concentrations 
of the standard solutions were established low, medium and high values (n=3 each). The 
formula utilized to the compare the peak area ratios was “B” PAR/ “A” PAR = %Matrix 
effect. 
2.5.4 Pharmacokinetic study 
The animal experiment and protocol were reviewed and approved by the Institutional 
Animal Care and Use Committee at Texas Southern University. The jugular veins of six 
male adult Sprague Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) weighing 
250-300g were cannulated under anesthesia the day before the study. Each rat was given a 
1mg/kg of racemic warfarin intravenous followed by 25mg/kg etravirine intravenous. 
www.intechopen.com
 
Tandem Mass Spectrometry – Applications and Principles 
 
362 
Serial heparinized blood samples (approximately 250µl) were collected from the jugular vein 
cannula for up to 144h. After centrifugation, the plasma samples were collected, 
immediately stored in -800C and analyzed within a week. 
3. Results and discussion 
3.1 Chromatographic conditions 
The chromatographic run times for the protein precipitated plasma samples were 11 
minutes. Retention times 2, 6.02, 7.76, and 9.5 minutes were observed for internal standard, 
R-warfarin, S-warfarin and etravirine, respectively. Figure 2 illustrates chromatograms 
obtained from blank rat plasma, spiked drug concentrations in plasma and after 
administration of the drug at 8 hours. These chromatograms demonstrate peak separation at 
the baseline excluding in vivo matrix interference. 
 
 
 
 
 
 
 
 
 
Fig. 2. (A) 
Blank rat plasma of (149/107 Da) 
Blank rat plasma (307/161) 
Blank rat plasma (432.9/141.6) 
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Fig. 2. (B) 
R-Warfarin 1ng/ml in plasma 
S-Warfarin 1ng/ml in rat plasma 
Etravirine 1ng/ml in rat plasma
 Internal standard  
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Fig. 2. (C) 
Etravirine 500ng/ml
R-Warfarin 500ng/ml 
S-Warfarin 500ng/ml 
Internal Standard 
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Fig. 2. Chromatograms of: (A) blank rat plasma; (B) Blank rat plasma spiked with 1ng/mL 
racemic warfarin, etravirine and the internal standard; (C) Blank rat plasma spiked with 
500ng/mL racemic warfarin, etravirine and the internal standard; (D) Plasma sample from a 
rat at 8 hours after concomitant intravenous administration of 1mg/kg dose of racemic 
warfarin and intravenous 25mg/kg dose of etravirine. 
R-Warfarin  
S-Warfarin  
 Etravirine  
Internal Standard 
D
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3.2 Linearity, sensitivity and detection limit of the assay 
Linear relationships were determined by the ratios of the peak areas of analytes to that of 
the internal standard over the range of 2.5-500ng/mL. Table 1 shows the intra- and inter-day 
assay changeability of the calibration curves. The lowest limits of detection for all analytes 
were 1 ng/mL. The lowest limit of quantitation for R-warfarin, S-warfarin, and etravirine 
were 5, 5 and 2.5 ng/mL, respectively.  
 
 
 
 
 
 Y-intercept Slope R2 
R-Warfarin 
Intra-day (n=3) 
Mean 0.0360 0.0640 0.9990 
SD 0.0090 0.0020 0.0010 
Precision (CV%) 25.73 5.6 0.1 
Inter-day (n=5)    
Mean 0.0256 0.0707 0.998 
SD 0.0031 0.0029 0.002 
Precision (CV%) 12.06 4.0 0.2 
S-Warfarin 
Intra-day (n=3) 
Mean 0.1681 0.0580 0.9980 
SD 0.0503 0.0019 0.0010 
Precision (CV%) 30 6.4 0.1 
Inter-day (n=5)    
Mean 0.0255 0.0634 0.9970 
SD 0.0216 0.0046 0.0040 
Precision (CV%) 84.4 7.3 0.4 
Etravirine 
Intra-day (n=3) 
Mean 0.0453 0.0062 0.9970 
SD 0.0012 0.0029 0.0030 
Precision (CV%) 2.6 23.4 0.3 
Inter-day (n=3)
Mean 0.0160 0.0059 0.998 
SD 0.0055 0.0005 0.003 
Precision (CV%) 34.58 9.3 0.3 
CV% = (standard deviation/mean)×100. 
 
 
 
Table 1. Linearity of calibration curves for warfarin-R in rat plasma. 
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Theoretical concentration 
 Low (10 ng/mL) 
Medium 
(100ng/mL) 
High (400 ng/mL) 
R-Warfarin 
Intra-day (n=6) 
Mean 9.84 94.19 435.68 
SD 0.41 6.60 33.70 
Precision (CV%) 4.1% 7% 7.7% 
Accuracy (% bias) 1.6% 5.8% 8.9% 
Inter-day (n=18) 
Mean 8.90 97.34 406.44 
SD 0.89 10.0 5.65 
Precision (CV%) 10.0% 10.27% 1.40% 
Accuracy (% bias) 11% 2.7% 1.6% 
S-Warfarin 
Intra-day (n=6) 
Mean 9.93 97.7 409.18 
SD 0.59 6.15 34.5 
Precision (CV%) 6% 6.3% 8.4% 
Accuracy (% bias) 0.7% 2.3% 2.3% 
Inter-day (n=18) 
Mean 9.20 101.55 403.11 
SD 0.74 3.84 5.26 
Precision (CV%) 8.08% 3.7% 1.31% 
Accuracy (% bias) 8% 1.2% 0.78% 
Etravirine 
Intra-day (n=6) 
Mean 12.7 109.18 438.3 
SD 1.42 11.5 63.73 
Precision (CV%) 11.07% 10.5% 14.5% 
Accuracy (% bias) 27% 9.1% 9.5% 
Inter-day (n=18) 
Mean 10.88 98.87 416.00 
SD 0.47 8.99 23.15 
Precision (CV%) 4.32% 9% 5.6% 
Accuracy (% bias) 8.8% 1.13% 4% 
CV% = (standard deviation/mean)×100. 
% bias = [(measured concentration-mean theoretical concentration)/measured concentration]×100. 
 
Table 2. Precision and accuracy of the simultaneous assay method for R- warfarin, S-
warfarin and etravirine in rat plasma. 
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3.3 Extraction recovery 
The plasma concentration range of  2.5-500 ng/mL displayed a mean recovery rate (n=3) of 
R-warfarin, S-warfarin, etravirine 121%± 0.06, 125.5% ± 0.08, 108.6%± 0.40, respectively. The 
mean recovery was calculated from the ratio of the slopes of the analytes calibration curves 
in plasma to that in mobile phase.  
3.4 Accuracy and precision of the assay 
To investigate the intra-day and inter-day precision and accuracy in rat plasma; low, 
medium, and high quality control spiked plasma samples were used. Table 2 illustrates the 
intra-day (n=6) and inter-day (n=3) quality control samples for racemic warfarin and 
etravirine. 
3.5 Stability 
Stability results in plasma were summarized in Table 3. The racemic warfarin and etravirine 
quality control samples were not affected by the three freeze-thaw cycles. Racemic warfarin 
and etravirine were stable in plasma under refrigeration conditions and room temperature 
for up to 12 hours. 
 
 
Storage 
condition 
Nominal 
concentration 
 
R-Warfarin 
Mean (+ SD) 
percent of 
nominal 
concentration 
remaining (n=3) 
S-Warfarin 
Mean(+ SD) 
percent of 
nominal 
concentration 
remaining (n=3) 
Etravirine 
Mean(+ SD) 
percent of 
nominal 
concentration 
remaining (n=3) 
4oC 
temperature for 
12 hours in rat 
plasma 
10 ng/mL 
100 ng/mL 
400ng/mL 
97.0  + 0.46 
96.0 + 2.47 
99.5 + 11.79 
103.0   + 0.38 
99.0     + 3.27 
105.5   +   18.16 
108.5   +   0.89 
95.2     +   0.17 
98.8     +   11.69 
Room 
temperature in 
the autosampler 
for 12 hours in 
rat plasma 
 
10 ng/mL 
100 ng/mL 
400ng/mL 
96.3  +  0.37 
97.2  +   12.29 
103   +   63.4 
102.2  +  0.16 
96.6   +   10.17 
103.5  +  66.6 
102 +  1.24 
114  +  22.1 
83  +  110.8 
Freeze-thaw 
Cycle 1 
 
 
 
Cycle 2 
 
 
 
Cycle 3 
 
 
 
10 ng/mL 
100ng/mL 
400 ng/mL 
 
10 ng/mL 
100ng/mL 
400 ng/mL 
 
10 ng/mL 
100ng/mL 
400 ng/mL 
 
74.29  ± 0.37 
69.30 ± 0.63 
92.58+  8.38 
 
78.8  + 0.03 
71.58 ± 0.43 
100.31  +  4.23 
 
76.78  + 0.21 
82.28  ± 3.62 
112.82  +  68.23 
 
81.88 ± 0.73 
77.71 ± 1.52 
82.64  ± 3.59 
 
89.6  +  0.31 
81.5 ± 2.38 
90.39  +  24.33 
 
85.63  +  0.14 
91.46  ± 4.67 
111.17 +  76.69 
 
107.43 +  0.31 
92.93 ± 1.41 
91.90 ± 25.63 
 
121.88  ± 0.18 
102.45  ± 5.22 
107.63 +   10.73 
 
133.4+  2.7 
150.97  ± 19.24 
94.55  +  19.47 
 
Table 3. Stability of warfarin and etravirine in rat plasma. 
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3.6 Matrix effect 
The matrix factor percentages of 118.2±10.9, 114±5.8, 143.6±17.57 for warfarin-R, warfarin-S, 
and etravirine were obtained. These results are in agreement with international guidelines 
(FDA, 2001).  
3.7 Application of the assay method 
The analytical method was applied to study the pharmacokinetics of concomitant 
administration of racemic warfarin and etravirine using the rat as an animal model (Figure 3 
and 4).  
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Fig. 3. Mean (± SD; n=6) plasma concentration – time profile of R-warfarin and S- Warfarin 
after an intravenous 1mg/kg  dose of racemic warfarin to male Sprague Dawley rats. 
The mean (± SD) areas under the plasma concentration curve for R-warfarin, S-warfarin, and 
etravirine were 30000 ±5584.4, 32009 ±10231, and 5203.5 ± 500 ng x hr/mL, respectively. The 
half-lives for these analytes were 7.5 ± 10.7, 16 ± 7, and 22 ± 11 hrs, respectively. 
Furthermore, these analytes exhibited clearances of 39.5 ±12.8, 31.6± 12 and 4.6 ± 0.0002 
mL/hr, respectively. The volumes of distribution for R-warfarin, S-warfarin, and etravirine 
were calculated to be 414 ±162.4, 637.5 ± 554, and 144 ±72 mL, respectively. Based upon 
these findings it can be suggested that R-warfarin is metabolized and eliminated quickly. S-
warfarin has a longer half-life and is not cleared as quickly as R-warfarin. Therefore, this 
demonstrates that S-warfarin is the more potent enantiomer, circulating  longer throughout 
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the body, and has the potential for eliciting more therapeutic efficacy. Etravirine 
demonstrated a decrease in clearance,  suggesting the saturation of the metabolic pathways 
responsible for it’s clearance upon concomitant administration with warfarin. Further 
pharmacokinetic studies are underway to examine the steady state drug interactions upon 
concomitant administration of racemic warfarin and etravirine.  
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Fig. 4. Mean (± SD; n=6) plasma concentration – time profile of etravirine after an 
intravenous 25mg/kg  dose of  etravirine  to male Sprague Dawley rats. 
4. Conclusion 
In conclusion, we have developed a rapid, simple and sensitive LC-MS/MS assay using a 
chiral column, for the simultaneous detection and quantification of R-warfarin, S- warfarin 
and etravirine in small volumes (100µl) of rat plasma. This method enabled us to do the 
simultaneous pharmacokinetic evaluation of intravenously administered racemic warfarin 
and etravirine using Sprague-Dawley rat as an animal model. Among the two enantiomers 
of warfarin, the S warfarin is more potent and stays in the body for a longer period of time 
as observed from its longer half life. This observation is in agreement with the previous 
studies on the pharmacokinetics of racemic warfarin reported by Eli Chan et al. 2009 and 
others. Furthermore, upon concomitant administration of etravirine and racemic warfarin, 
there is a statistically significant increase in the half life of etravirine which is a clear 
indication of a drug-drug interaction between these two commonly administered 
pharmaceuticals. Hence the concomitant administration of warfarin and etravirine could 
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increase the efficacy of this NNRTI due to the above mentioned reasons. Due to the limited 
pharmacokinetic studies for etravirine in the literature, we need to proceed further with 
similar studies to fully understand the therapeutic impacts of this combination drug 
regimen. Hence this study can be used for preclinical analysis which can be applied for 
further pharmacokinetic characterization of racemic warfarin with etravirine. 
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